The webinar will focus on how vaccination programmes can be successfully integrated into dairy herds.
The session will explore how the five-point cryptosporidiosis control plan can guide client discussions, how extended colostrum feeding can be implemented on-farm, and practical strategies covering hygiene, transition milk, and wider scour control.
Alex Cooper MRCVS from Fenton Vets (pictured) and his client, dairy farmer Lottie Wilson from Mountain Park Farm, Pembrokeshire, will talk about the challenges they faced with cryptosporidiosis and how they implemented management changes to overcome these issues, resulting in a herd now largely free from scour.
MSD Veterinary Adviser, Kat Baxter-Smith MRCVS, said: “Vaccination plays a crucial role in controlling cryptosporidiosis, and strong vaccine sales reflect the clear demand for effective on-farm solutions.
"This webinar will explore those challenges, share the latest research and provide first-hand farm experience to help vets move scour management from reactive treatment to proactive prevention.”
https://thewebinarvet.com/webinars/making-cryptosporidiosis-vaccination-work-on-farm-practical-insights-for-vets
PORCILIS PCV M Hyo ID is a ready-to-use intradermal vaccine that protects against Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo).
The vaccine can be mixed with PORCILIS Lawsonia ID and administered on the same day (though not mixed) with PORCILIS PRRS, allowing piglets to be protected against four diseases during a single intervention using MSD’s IDAL Twin needle-free device.
MSD says this will streamline vaccination protocols, with IDAL administration offering “less pain and stress for pigs”.
Needle-free administration is also designed to reduce the risk of iatrogenic transmission of pathogens between pigs and remove the risk of broken needles.
The vaccine combines PCV2 and M. hyo in a low-volume 0.2 ml dose and can be administered from three weeks of age, including in pregnant and lactating sows.
That'll bring the GB list price down from £434 to £347.20, something which can only be good news at a time when the veterinary profession is facing greater scrutiny over the cost of care than ever before.
The company says it will also be increasing the product discount, which can be discussed with its Account Managers.
MSD says the price drop makes Bravecto Injectable the most affordable way to protect dogs with Fluralaner and highlights the convenience of annual dosing and the fact that it avoids tricky discussions about where to buy the product.
https://www.msd-animal-health.co.uk/
The webinar, which is exclusively for veterinary professionals, will include a Q&A session addressing common concerns around vaccination timing, use in Johne’s-positive herds, the role of extended colostrum feeding, and the growing issue of antimicrobial resistance.
Speakers for the event are:
Kat Baxter-Smith, Veterinary Advisor at MSD Animal Health (pictured), said: “Vaccination has an important role to play in cryptosporidiosis control, but we know that for some practices, concerns remain — particularly around colostrum management and use in herds with Johne’s.
“This session is about opening up those discussions, sharing the latest research, and addressing the barriers that may be holding back wider adoption.
"Our aim is to support vets in moving scour management from reaction to prevention.”
https://view6.workcast.net/register?cpak=7702733614498733
The March 2025 Cattle Highlights Report from the Royal GD in the Netherlands has revealed that the proportion of paromomycin-resistant isolates has jumped from 48% in 2021 to 72% in 2024.
The report also highlights an increase in the detection of cryptosporidiosis in calves up to 14 days of age.
MSD says that while it is unclear whether paromomycin is being used to treat E.coli or cryptosporidiosis, the rising use of the antibiotic could be contributing to greater exposure and increased resistance in E.coli K99.
Kat Baxter-Smith MRCVS (pictured), a vet advisor at MSD Animal Health, said: “What we need now is a mindset shift—moving away from routine antibiotic use and towards a more robust, preventative management strategy.
“It’s not about eliminating treatment altogether but using it only when it is really needed.”
“Vaccination, clean pens, and ensuring that every calf receives the right volume and quality of colostrum are the real cornerstones of effective scour control.
“Using vaccines such as Bovilis Rotavec Corona for rotavirus, coronavirus, and E.coli and Bovilis Cryptium for Cryptosporidium parvum is one of the most effective ways to reduce the incidence of neonatal diarrhoea.
"By vaccinating the dam, we ensure the calf has the best possible immunity at birth by ingesting the fortified colostrum and transition milk in the first days of life, which significantly reduces reliance on antibiotics and minimises disease risks.”
The report emphasises best-practice principles such as effective colostrum management, good hygiene and housing, balanced dry cow transition and strategic vaccination of the dam.
The report also recommends halofuginone (Halocur) as the first-line treatment for cryptosporidiosis, due to its targeted action and significantly lower risk of contributing to AMR.
Kat added: "By embracing these proactive strategies, vets and farmers can take a crucial step towards safeguarding calf health, reducing reliance on antibiotics, and combating the growing threat of antimicrobial resistance.”
https://issuu.com/gezondheidsdienstvoordieren/docs/highlights_report_cattle-march_2025
Bravecto Triuno is approved for the treatment of tick and flea infestations in dogs (Ctenocephalides felis, C. canis, Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, and Rhipicephalus sanguineus).
It is also approved for the treatment of infections with roundworms (adult stages of Toxocara canis and Toxascaris leonina) and hookworms (L4, immature adult (L5), and adult stages of Ancylostoma caninum and Uncinaria stenocephala), for the prevention of heartworm disease (caused by Dirofilaria immitis), and for the prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).
Victoria Miles, UK Companion Animal Director, MSD Animal Health, said: “With this latest formulation of Bravecto, MSD Animal Health is giving veterinarians and dog owners a greater range of convenient options for protecting their dog year-round from parasites, and all from the same trusted Bravecto portfolio.”
She added: “We see Bravecto Triuno as a great option for puppies that require a monthly wormer on top of protection against fleas and ticks.
"This also gives flexibility later on for the dog to remain with the Bravecto brand but be swapped onto a longer-duration flea and tick product with a wormer administered according to a veterinarian’s risk-based assessment.”
Bravecto Triuno is available as a flavoured chewable tablet indicated for dogs and puppies from 8 weeks of age and at least 1.27 Kg body weight and can be administered monthly to dogs at risk of infestation by multiple types of internal and external parasites.
It contains three anti-parasitic ingredients including fluralaner, which provides activity against ticks and fleas, moxidectin, which provides systemic activity against non-intestinal worms, and pyrantel, which provides activity against intestinal worms.
https://www.noahcompendium.co.uk/?id=-488423
This new injectable fluralaner formulation is approved for the immediate and persistent killing of fleas for one year (Ctenocephalides felis and Ctenocephalides canis), from 3 days to 12 months after treatment for the ticks Ixodes ricinus, and Dermacentor reticulatus, from 4 days to 12 months after treatment for Rhipicephalus sanguineus, and from 7 days to 12 months after treatment for Ixodes hexagonus.
MSD says it will also reduce the risk of Babesia canis via transmission by Dermacentor reticulatus from day 3 after treatment for up to 12 months, and also reduces the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis for up to 12 months.
Victoria Miles, UK Companion Animal Business Unit Director, MSD Animal Health said: “Imagine not having to worry about flea and tick protection for a whole year."
Bravecto 150 mg/ml powder and solvent for suspension for injection for dogs can be administered to dogs and puppies six months of age and older.
The product is already available in France and Germany and MSD told VetSurgeon.org that stocks are expected in the UK in September, for which the company is now taking pre-orders.
Contact your MSD Account Manager for further information on pricing.
Bovilis Nasalgen-C can be used for the active immunisation of calves from the day of birth onwards to reduce clinical signs of upper respiratory tract disease and nasal viral shedding from infection with BCoV.
MSD says respiratory disease in UK calves is widespread and comes at a high cost from an emotional and business productivity perspective.
It is also continually highlighted as a critical area for overuse of antibiotics.
Despite all this, there is an under use of vaccination in the UK cattle sector1.
Speaking at BCVA last week, Paul Burr MRCVS, director of Biobest Laboratories said: “Recent UK studies show bovine coronavirus being the most prevalent virus found in routine disease screening and nasal swab samples taken during a bovine respiratory disease outbreak.
"BCoV was found in 39% of over 400 nasal swab samples taken between 2020 and 2022 from BRD affected cattle on UK farms2.”
Kat Baxter-Smith, veterinary adviser with MSD Animal Health, said: “Whilst the pathogenicity of BCoV within the BRD complex remains an unknown quantity, its ubiquitous presence in the UK cattle population – and the recent human experience of coronavirus as a significant respiratory pathogen – suggests a need for a re-evaluation of BRD control by vets and farmers.
“Just as coronavirus is a pathogen associated with the common cold and Covid-19, BCoV is a proven pathogen that directly impacts the calf respiratory tract.
"Consequently, the availability of this new BRD vaccine presents veterinary professionals with another tool in their armoury to improve control of this costly disease.
“If diagnostics suggest BCoV is implicated in any BRD problem, the availability of Bovilis Nasalgen-C allows UK cattle farmers to effectively administer protection for young calves via a single 2ml intranasal dose that can quickly reach the site of action.
"This will support the development of immunity against BCoV early in life, the onset of which starts five days after administration and has a 12-week duration.”
Bovilis Nasalgen-C comes can be used on the same day with Bovilis INtranasal RSPÔ Live, which offers protection against both Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3).
Bovilis Nasalgen-C can be stored for up to 24 hours at room temperature after reconstitution, can be given to cattle using a syringe or applicator device and is available in one, five and 20 dose packs, suitable for both small and large herds.
References:
MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
References
MSD says the new chip is compliant with ISO standards, has proven temperature accuracy1 and as yet is the only microchip on the market that combines identification and temperature monitoring.
The HomeAgain Thermochip has been designed to work for the lifetime of the pet, and it's being launched alongside the HomeAgain Pet Recovery Database, which is free of charge.
Michael Morrow BSc BVSc MRCVS, Director of St Vincents Veterinary Surgery in Wokingham, has been involved in trials of the new chip. He said: ''The launch of HomeAgain Thermochip is a real game-changer in the market.
“We have been trialling the Thermochip for some time and it’s now our default option to measure temperature.
"It’s incredibly useful in everyday practice, particularly when it comes to fractious cats or extremely nervous dogs, and it improves efficiency in consultations.
"We also use the Thermochip extensively during anaesthetic and post operative monitoring – with minimal handling.
“Reassuringly, we’ve never had any issues with the microchip reader or with the chip migrating to other parts of an animal’s body so it’s very reliable.”
In addition to the benefit of being able to measure temperature in a non-invasive way, MSD points to recent studies which suggest that a pet’s ‘normal’ temperature is not a specific number, rather a range of values that depend on numerous factors such as the time of day, the site of measurement, sex, breed, size, age, activity and stress levels2.
The HomeAgain Thermochip makes it easier to take multiple temperature readings easily over time, thereby establishing a pet’s individual temperature range.
For animal identification, the microchip works in much the same way as other microchips.
Once the owner registers their pet’s microchip with a recovery database, their animal – in theory – can be traced if lost.
The reality is often different, because owners' contact details are frequently out of date, making it difficult to reunite pets.
MSD says it aims to have the most comprehensive reunification platform, with a database which:
For more information, visit: homeagain.co.uk
Reference
The Suckler Herd Performance Checklist is designed to help veterinary surgeons and farmers work together to draw up a workable action plan to address the main areas influencing optimum herd health and performance.
The new app works on tablet computers, as well as Apple and Android smartphones, and allows vets to e-mail audit results directly to farmer clients following an interactive on-farm assessment.
MSD Animal Health’s beef and youngstock marketing manager Robert Simpson said: “This additional engagement tool helps a vet assess performance across the five crucial time periods and processes impacting on the efficiency of beef suckler herds.
“For example, reducing calf morbidity and mortality rates in a suckler herd starts with management practices before conception.
"Optimum performance also requires following proper management protocols throughout the youngstock period from birth to weaning, including effective colostrum administration, vaccination, nutrition and hygiene.
“It can also be used to provide confidence to vets who are less experienced with suckler herds, allowing them to follow a structured evidence-based approach when on farm,” he said.
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life and that the onset of immunity for BRSV is 6 days (for calves vaccinated from the day of birth onwards) and 5 days (for calves vaccinated from the age of one week onwards).
Onset of immunity for Pi3V is one week after vaccination. The duration of immunity is 12 weeks for both viruses.
From a practical standpoint, the new license means Bovilis Intranasal RSP Live can now be used on farm at the same time as other early life interventions associated with newborn calves – for example, colostrum/first milk feeding, navel management, tagging, jacketing and necessary pen movements.
Additionally, Bovilis Intranasal RSP Live can be used up to six hours after mixing with the solvent, which MSD says is the longest of all the available intranasal vaccines for these pathogens.
The vaccine is supplied as a nasal suspension product that doesn’t need a specific applicator – although for maximum flexibility an easy-clean injector and nozzle kit is available for vaccinating multiple animals.
The vaccine is available in 5x1 dose, 5 dose and 5x5 dose packs.
The app, which works on tablets and smartphones, allows vets to e-mail audit results directly to clients following an interactive calf health assessment at the farm.
MSD Animal Health’s youngstock marketing manager Robert Simpson said: “Our new app allows both parties to explore, record and score calf health performance across five core areas to identify the strengths and weaknesses of any rearing unit’s environment and processes.
“Working through a series of 10 questions within each core area – designed to tease out where a rearing unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to monitor progress against agreed targets”.
For more information about the app, contact your MSD account manager.
The new Flock Health Checklist is designed to helps practitioners assess performance across the three crucial time periods and two key management processes which have an impact on the success of sheep enterprises.
Dr Kat Baxter-Smith, veterinary adviser with MSD Animal Health said: “We have developed this new performance checklist drawing on specialist sheep vet working experiences, clinical research studies, economic data and industry recommendations.
"For example, the pre-breeding period is a great time to make sure ewes and rams are as fit and healthy as possible.
"Good practice and preparation in this area will go a long way to minimising stress and problems during a busy lambing period.”
Late pregnancy and lambing period is also a vital time – and is the busiest few weeks on any sheep farm.
Kat added: “Having pre-agreed protocols for this important period in the sheep farming calendar – and keeping a record of issues that arise – will go a long way to making sure subsequent lambing seasons go as smoothly as possible.”
Growth, weaning and sale is the third crucial time period and the Flock Health Checklist incorporates an additional series of audit-based questions designed to pinpoint system strengths and weaknesses.
The Flock Health Checklist also enables vets to ask a series of questions covering two key management processes: disease management and biosecurity; and how flock performance is currently monitored.
Kat said: “Working through a series of 10 questions within each of the three crucial time periods and two key management processes – designed to tease out where a sheep unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to montor performance against agreed targets.
“Similar types of checklist have been available to dairy youngstock rearing units and beef suckler herds for a couple of years now, with several vets reporting that these tools have proved integral to their productivity improvement work with farmer clients.
"Use of this checklist-based approach is also helping better implementation of preventative health practices such as vaccination. We hope this latest tool will help the GB sheep industry similarly.”
For further information, contact your local MSD Animal Health account manager.
Bovilis Bovivac S is used for active immunisation to induce serological and colostral antibody production against Salmonella Dublin and Salmonella Typhimurium.
In the face of an outbreak, it can also be used to reduce Salmonella Typhimurium infections when used as part of an overall herd management programme.
MSD says Bovilis Bovivac S may also contribute to reducing S. Typhimurium contamination of the environment. Other than the packaging, the vaccine itself is identical.
Rubén Del Pozo Sacristán (pictured right), technical manager for pigs at MSD Animal Health UK, will be delivering the seminars.
He said: “At MSD Animal Health UK, we’re committed to helping further the knowledge and expertise of vets, so we have put together a series of seminars which will focus on common and demanding production challenges and diseases facing pig producers.”
The monthly seminars will be suitable for all vets, but especially those who are new to pig medicine.
Each seminar will be worth two to three hours of CPD time, with certificates available for all participants.
Rube added: “Of the 12 seminars we have planned, we’re hoping to hold four of these in a face-to-face capacity, with dinner included for those who attend, to allow for networking and further discussion.
The programme is as follows:
For more information on the academy, or to register your interest, speak to your MSD Animal Health account manager.
The company says that with an estimated 3.2 million UK households welcoming a new pet into their family home during lockdown1, many experienced and new dog owners will be unaware of the risks to their dog of CCC when it socialises, hence the new risk assessment tool, which is available at: https://www.msd-animal-health-hub.co.uk/KBPH/contagious-canine-cough-risk-assessment.
The risk assessment campaign will be supported with 'Does your dog ...' posters for vets, information and advice for dog owners on the website and a social media campaign encouraging dog owners to spread the information to other dog owners.
Carley Chutter, Nobivac(r) Product Manager at MSD Animal Health said: "With so many new dog owners now socialising more, taking their dogs on holiday and even considering taking their dogs into the office, protecting their dogs as they socialise is vital.
"Currently only an estimated 1 in 3 vaccinated dogs in the UK are also covered against Bordetella2 so the 'Ask us to protect your dog' resources offers the chance for practices to start the conversation about protection with clients.
"A common barrier to vaccinating against CCC is the belief that it is only necessary for dogs going into kennels, rather than all social dogs. Most dogs meet others, however, while out walking, during training, or while attending the vets, CCC is infectious even at low levels. Indeed, dogs can be asymptomatic but infectious.
"So, improving protection levels against this disease which is distressing for both the owner and dog, is important in both reducing the risk of outbreaks and the need for antibiotic treatment."
Nobivac(r) Respira Bb injectable vaccine against Bordetella bronchiseptica, gives 12 months protection when used as a single-dose booster in dogs previously vaccinated with Nobivac(r) KC. Dogs not previously vaccinated against Bordetella bronchiseptica require two doses administered four weeks apart. Duration of immunity is 7 months after the primary course and 12 months after a booster with Nobivac(r) Respira Bb. It may also be given 12 months after a primary course in cases where the 7 months dose is missed.
To support the use of Nobivac(r) Respira Bb a range of tools are available to practices and further information can be found at www.nobivacrespiraBb.co.uk, or contact your MSD Animal Health account manager.
Three bursaries are available - two in ruminant and one in companion animal research, each worth up to £4,000.
Annabelle Mohring, Veterinary Advisor at MSD Animal Health said: "We appreciate that the last 18 months have been challenging for many veterinary surgeons and adding new research to this may not be considered a priority. But with the pace of change rapidly increasing, improving business skills and scientific knowledge will become more important than ever for the profession.
"Research forms the foundation of the industry and being awarded a bursary has proved to be a career-changing experience for some participants. We're now welcoming applications as part of our investment in the veterinary community."
Each project should be completed within one to two years and the veterinary surgeon proposals will be judged by objective third party university academics to ensure independent assessment.
The deadline for the MSD Animal Health Veterinary Surgeon Research Bursaries is 30th November 2021.
For further information, visit: www.msdahresearchbursary.co.uk.
Photo: Hattie Barnes who was awarded the 2020 Veterinary Surgeon Bursary in the companion animal sector. She was awarded £4,000 for her analytical, cadaver-based study to investigate different draping protocols in elective orthopaedic surgery. Hattie is currently undertaking a 3-year residency in Equine Surgery at the University of Liverpool.
MSD says the Summer Staycation campaign is designed to support the needs of new dog owners and those taking their dogs to areas outside their local region, where parasites risks will be different.
The campaign offers veterinary practices a range of resources, including client emails, a downloadable guide to parasites, social media posts and an interactive risk checker on the Keeping Britain's Pets Healthy website. There is also some training for front of house staff and receptionists at https://www.msd-animal-health-hub.co.uk/cpd/staycation.
Nicola Barclay, Senior Product Manager at MSD Animal Health said: "Summer holidays will be taking a different form this year with most people planning trips in the UK, making it more likely they will take their pets.
"What's important is that seasoned and new owners alike are aware of the parasite risks in the places they're visiting so they aren't putting the health of their pets at risk.
"We're therefore providing a range of resources to help veterinary practices encourage pet owners to make sure there are no breaks in their parasite protection and vaccinations and that they are appropriately protected for the places they'll be visiting."
Dr Ian Wright, Head of ESCCAP UK & Ireland added: "The research findings from The Big Tick Project in 2015 found that 1 in 3 dogs coming into veterinary practices during the summer months had ticks on them.
"Research is also showing many parasites extending their range with an increased risk of human and pet exposure. Warming temperatures mean that ticks can be encountered all year round in the UK, carrying potentially dangerous pathogens to dogs and people including Lyme disease and Tick-borne encephalitis virus (TBEV).
"With so many new dog owners and people being more likely to holiday in the UK, making sure dog owners understand the risks, while keeping them in proportion, and giving appropriate protection advice is vital.''
For more information, contact your MSD Animal Health account manager.
The research project, which is being carried out by RVC student Collette Taylor for her PhD, is looking at the development of novel diagnostic targets to establish the specific leptospira implicated in canine clinical cases.
Collette said: "Existing leptospirosis diagnostics have a number of limitations. MAT serological testing may provide information that can be supportive of a serogroup diagnosis but may also provide false positives due to previous vaccination or indeed be confounded by cross-reactivity. It can also be difficult to interpret serology in the absence of paired samples.
"PCR tests are sensitive, usually specific, but are dependent on timing of sampling and do not tell you which serovar is concerned.
"My research is focused on offering more specialised diagnostic tests which can differentiate antibodies associated with infection from those due to vaccination. Extending this theme, our group is interested in further typing of samples where the Leptospiral DNA is identified using Multi-locus sequence typing (MLST). I am now at the stage of validation and we are able to offer additional testing of serum or blood test samples from confirmed clinical cases."
If you'd like to send in a sample for further tests, you will need to complete a questionnaire, and samples must be from confirmed cases of leptospirosis that have already undergone leptospirosis diagnostics from another laboratory.
John Helps, Senior Technical Manager, Companion Animals, MSD Animal Health said: "As a 3rd year PhD student Collette has two main areas of study. The first is looking at the risk factors of leptospirosis including ecological niche modelling for specific serogroups in different regions across the country. The second part is the development of new specialised diagnostic tests that can provide better targeted serological approaches to diagnosis of this disease."
"As a potentially serious zoonosis, leptospirosis is an important differential diagnosis for a variety of canine disease presentations. These include not only acute renal or hepatic disease; it should also be on the differential list in conditions such as uveitis and retinal bleeding, acute respiratory distress, and haemorrhagic gastoenteritis when parvovirus is excluded.
"Collette's highly valuable research expands understanding of the epidemiology of canine leptospirosis within the UK. Veterinary practices that take advantage of this scheme will gain a better understanding of locally relevant disease data which is likely to better inform the approach to dog vaccination."
For further information contact Collette Taylor at ctaylor18@rvc.ac.uk.
The company hired Onswitch to call 700 veterinary practices and ask about kennel cough. 43% of callers were told it was up to them whether their dog had a vaccine for CIRD, with no clear recommendation in over 50% of calls.
MSD says that there was very little detailed information given about CIRD or kennel cough or vaccinations, with nothing at all mentioned in 18% of calls.
Whilst 18% of calls mentioned that dogs can contract kennel cough mixing with other dogs, 9% were told that their dog would only need the vaccination if it was going into kennels!
According to the company, vaccination for Bordetella bronchiseptica and canine parainfluenza virus has declined dramatically during lockdown, with over 350,000 less doses being bought in 2020 vs 2019 April - December1, however the risks are still prevalent, because dogs are still mixing.
Michelle Townley, Veterinary Advisor for the Companion Animal team at MSD Animal Health said: "CIRD, more commonly known as kennel cough, is often mistakenly believed to be only a disease of kennels. The reality is that respiratory pathogens are most commonly transmitted between dogs that mix or share the same air space. This results in risk anywhere where dogs are being social, including parks, groomers and vet practices. Due to this confusion, we recommend referring to the disease with pet owners as contagious canine cough."
She added: "This data reveals a significant amount of confusion in the advice veterinary practices give to dog owners in relation to protection against CIRD,or contagious canine cough. Practice team members have often received no formal training on what to tell dog owners and how to discuss CIRD, so messages vary widely and are not always correct. This data reveals that there is a great opportunity for practices to proactively discuss contagious canine cough as a standard component of the annual vaccination programme and ensure more dogs that socialise with other dogs and are at risk get the protection they need."
For more information on the Nobivac vaccine range, vaccine protocols and product and team training, contact your MSD Account Manager or visit www.nobivacrespirabb.co.uk.
The new vaccine offers 12 months protection when used as a single-dose booster in dogs previously vaccinated with Nobivac(r) KC. It is presented in a 10ml multi-dose vial which can be stored in or out of a refrigerator for 28 days after broaching.
Dogs not previously vaccinated against Bordetella bronchiseptica need two doses administered four weeks apart.
The duration of immunity is 7 months after the primary course and 12 months after a booster with Nobivac(r) Respira Bb. It can also be given 12 months after a primary course in cases where the 7 month dose is missed.
Blaise Scott-Morris, Product Manager, MSD Animal Health said: "Currently only an estimated 1 in 3 vaccinated dogs in the UK are also covered against Bordetella1 so Nobivac(r) Respira Bb offers the chance for practices to re-start the conversation about protection with clients.
"A common barrier to Canine Infectious Respiratory Disease (CIRD) protection, caused by Bordetella, is the belief that it is only necessary for dogs going into kennels, rather than all social dogs. Most dogs meet others however, while out walking, during training, or while attending the vets, and CIRD is infectious even at low levels. Indeed, dogs can be asymptomatic but infectious.
According to the company, trials showed that dogs vaccinated with Nobivac(r) Respira Bb demonstrated a significant reduction in clinical signs of respiratory disease and a reduction in bacterial shedding2. It has also been safely demonstrated in a wide range of breeds3 and has proven efficacy in puppies challenged two weeks after the primary course of vaccination4. It can be given concurrently with many other Nobivac(r) vaccines.
MSD says the new vaccine is most suitable for dogs:
Further information can be found at www.nobivacrespiraBb.co.uk, or contact your MSD Animal Health account manager.
The materials available include a scour management guide for farmers and a more detailed version for vets. They encourage a focus on three main areas for improved, sustained disease control: maximising calf immunity; identifying any causal agents and how to effectively manage an outbreak of calf scour on farm.
MSD Animal Health veterinary adviser Dr Kat Baxter-Smith (pictured right) said: "Even with good disease prevention protocols in place, calf scour outbreaks can still occur. But when they do, remedial action should focus on these three key areas to resolve the outbreak as quickly as possible and reduce the chances of another costly event happening in the future.
The company highlights a 202 survey of more than 300 farms, which found that over 80% of UK calf rearing units had seen a case of scour in the previous 12 months; with 50% of farms admitting to experiencing calf deaths due to the disease1. Costs are estimated at £57.94 per case but this does not include the longer-term impacts of the disease on future calf productivity.2,3
Bovilis Rotavec Corona is used for the active immunisation of pregnant cows and heifers, 12-3 weeks pre-calving, to raise antibodies against rotavirus, coronavirus and E. coli F5 (K99). Calves gain protection by drinking the fortified colostrum from their vaccinated mothers.
The company says the new license indication will mean greater usage flexibility for UK cattle producers focusing on immunity-led prevention of infectious calf scours.
MSD ruminant veterinary adviser Dr Kat Baxter-Smith said: "On the old license, this vaccine needed to be used within eight hours of opening, so this will be a significant benefit-led change for suckler beef and dairy producers.
"For all-year-round calving dairy herds, for example – that may want to vaccinate successive pregnant dams on different days – it will make an opened bottle of vaccine last much longer. Those running batch calving herds with a long calving period should also benefit. We hope this will help reduce unnecessary wastage of the vaccine on farm and save farmers money.”
MSD says it will still be crucial to store the vaccine properly – upright and refrigerated (at 2-8°C) before and after broaching, and after first use. A broached vial will be able to be used once more during the next 28 days after the first vaccination event and then discarded. Vaccination equipment such as needles and syringes should be sterilized. Use of a multi-dose syringe to minimise vaccine contamination and excessive broaching is recommended.
The vaccine vials should still be shaken well before use. The injection should be made through an area of clean, dry skin with precautions taken against contamination.
The company announced last month that from 1st January next year, practices will have to order companion animal and ruminant products via either MWI or NVS (who will also fulfil the order), but will be invoiced direct by MSD.
Pig products will join aquaculture and poultry products to be supplied directly to customers by MSD Animal Health.
In its announcement, the company said that the new structure would allow the company to enhance the customer experience and more quickly adapt to changes in the market to better serve its customers.
VetSurgeon.org contacted the company for further clarification about how the customer experience would be improved.
The company explained that the two main benefits of the new structure concern price visibility and stock control.
A spokesperson for the company said: "Currently, customers may get a discount from us and separately a discount from wholesaler. With our new distribution model we will invoice monthly and all discounts will be on one invoice, so it will be easier to determine the actual price paid."
The spokesperson explained that with the old model, once stock was sold to wholesalers it would be allocated to customers, so there would be some held by MSD, some allocated and some in distribution: "The benefit of the new model is we will have full oversight of stock as it will be in our own warehouses or with distribution partners. If there are disruptions in the market, we will have better awareness of in market demand and we can allocate stock appropriately".